Skip to content

COMPLETED enrollment in our Phase 2 COVID-19 Clinical Trial

PARTNERING with BARDA in their DRIVe Solving Sepsis Initiative

HOME
ABOUT US
OUR SCIENCE
OUR PLATFORM
NEWS/EVENTS
PUBLICATIONS
CONTACT

Menu

HOME
ABOUT US
OUR SCIENCE
OUR PLATFORM
NEWS/EVENTS
PUBLICATIONS
CONTACT

News/Events

Exciting news, events and articles about plasma gelsolin therapy and BioAegis Therapeutics discoveries on infectious, inflammatory and degenerative diseases.

Vaccines Alone Are Not The Answer

by Susan L. Levinson, PhD | CEO BioAegis Therapeutics

Sepsis: The Hydra Within Us

by Steve Cordovano | Co-Founder BioAegis Therapeutics

Previous

Next

News

August, 2019: BioAegis Therapeutics Reports Favorable Safety and Pharmacokinetic Results in its Phase 1b/2a Dose-Escalation Study of Recombinant Human Plasma Gelsolin with Highest Doses Ever Administered to Patients

April, 2019: BioAegis Therapeutics Receives US Patent Protection for the Therapeutic Uses of Plasma Gelsolin in Renal Failure

March 2019: BioAegis Therapeutics Completes Enrollment in its Phase 1b/2a Dose-Ranging Safety Study of Recombinant Plasma Gelsolin for Community-Acquired Pneumonia

March, 2019: BioAegis Therapeutics Awarded European Patent Protection for the Uses of Plasma Gelsolin to Treat Infections

February 2019: BioAegis Therapeutics Expands Phase 1b/2a Community- Acquired Pneumonia Study to the Republic of Georgia — Successfully Completes Second of Four Dosing Cohorts

February 2019: BioAegis Therapeutics Announces Publication in “Clinical Infectious Diseases” Linking Depleted Plasma Gelsolin Concentrations at Admission to Severe Pneumonia Outcomes in CDC-Sponsored “Etiology of Pneumonia in the Community (EPIC)” Study

December, 2018: BioAegis Therapeutic’s Intellectual Property Portfolio Expands With Five Granted Patents in 2018

September, 2018: BioAegis Therapeutics Enrolls First Patients in Phase 1b/2a Community-Acquired Pneumonia Study and Raises $4 MM in Equity Round

June, 2018: BioAegis Therapeutics Abstract Presented at ASM-Microbe

December, 2017: BioAegis Therapeutic’s Intellectual Property Portfolio Expands With Six Granted Patents in 2017

November, 2017: Community Acquired Pneumonia Etiology Review in Clinical Infectious Diseases Reinforces Need for Host-Based Approach

October, 2017: BioAegis Therapeutics and the T.H. Chan-Harvard School of Public Health Demonstrate “Delayed Therapy with Plasma Gelsolin Improves Survival in Murine Pneumococcal Pneumonia” at ID Week

Page1 Page2 Page3 Page4 Page5 … Page7

Awards

Clinical Trials Arena Award - Best COVID19 Response

Events

October 6-7, 2020: BioNJ’s 10th Annual BioPartnering Conference

August 20, 2020: WIB-Metro New York – Biotech Leadership in the time of COVID-19: Impact, Opportunity, and Resilience

Tweets by BioAegis

Stay informed of our latest discoveries and news.

EMAIL

COMPANY DETAILS

LOCATION:
BioAegis Therapeutics
North Brunswick, NJ

MEDIA INQUIRIES:
Contact: Christine Lagana
clagana@bioaegistx.com

INVESTOR INQUIRIES:
Contact: Steven Cordovano
scordovano@bioaegistx.com

FOLLOW US

Facebook Twitter Linkedin Youtube

JOIN OUR TEAM

©2021 BioAegis® Therapeutics Inc. | Privacy Policy | Terms of Use